Rank	NCT Number	Title	Recruitment	Study Results	Conditions	Interventions	Sponsor/Collaborators	Gender	Age Groups	Phases	Enrollment	Funded Bys	Study Types	Study Designs	Other IDs	First Received	Start Date	Completion Date	Last Updated	Last Verified	Results First Received	Acronym	Primary Completion Date	Outcome Measures	URL
1	NCT01232374	Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma	Recruiting	No Results Available	Local Advanced Esophageal Squamous Cell Carcinoma	"Drug: Placebo, Radiotherapy and Chemotherapy|Drug: Nimotuzumab, Radiotherapy and Chemotherapy"	"Biotech Pharmaceutical Co., Ltd."	Both	Adult|Senior	Phase 2	144	Other	Interventional	"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)"	BT-ESO-1001	12-Oct-10	Aug-10	Feb-14	1-Nov-10	Jul-10	No Study Results Posted	null	Feb-11	Response rate of Nimotuzumab combined with chemo-irradiation|1-yr overall survivals|2-yr overall survival|3-yr overall survival|Local progression-free survival|Disease progression-free survival|Distant metastasis rate|Number and grade of Participants with Adverse Events|Quality of life	http://ClinicalTrials.gov/show/NCT01232374
2	NCT02384811	Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma	Recruiting	No Results Available	Esophageal Squamous Cell Carcinoma	Radiation: radiation	Fudan University	Both	Adult|Senior	Phase 2	74	Other	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	2014-86-882	2-Mar-15	Dec-14	Dec-19	9-Mar-15	Mar-15	No Study Results Posted	null	Dec-17	Local control rate|Overall survival|Safety: Frequencies of treatment-related adverse event categories by NCI-CTC	http://ClinicalTrials.gov/show/NCT02384811
3	NCT01551589	Elective or Prophylactic Nodal Irradiation for Esophageal Cancer	"Active, not recruiting"	No Results Available	Esophageal Squamous Cell Carcinoma	Radiation: docetaxel and cisplatin  concurrent chemoradiotherapy|Radiation: docetaxel and cisplatin	LANG Jin-yi|The Second People's Hospital of Sichuan	Both	Adult|Senior	Phase 3	320	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	CSWOG0001|BT-IST-SCCHN-037	4-Mar-12	Mar-12	Sep-15	8-Mar-12	Mar-12	No Study Results Posted	ENI or PNI	Sep-14	Local control rate/ Inside irrational field recurrence rate|3-year Overall survival(OS)|3-year Disease-free survival|Quality of life(QoL)|Safety and Tolerability	http://ClinicalTrials.gov/show/NCT01551589
4	NCT02123381	Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma	Recruiting	No Results Available	Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma	Radiation: preoperative radiotherapy|Drug: cetuximab	"Sichuan Cancer Hospital and Research Institute|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Affiliated Tumor Hospital of Guangzhou Medical University|Southwest Hospital, China|Xinqiao Hospital of Chongqing"	Both	Adult	Phase 2	100	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	scch2014019	13-Apr-14	Apr-14	null	7-Dec-14	Apr-14	No Study Results Posted	null	Apr-17	Expression of Survivin protein in Esophageal Squamous Cell Carcinoma before and after Radiotherapy|Expression of p53 in Esophageal Squamous Cell Carcinoma before and after Radiotherapy|changes of serum vascular endothelial growth factor（VEGF）level before and after radiotherapy|Quality of life (QOL)|Overall survival|PFS（progression-free survival）|local control rate（LCR）|Pathological remission|grade 3-5 adverse events	http://ClinicalTrials.gov/show/NCT02123381
5	NCT02272699	Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma	Not yet recruiting	No Results Available	Esophageal Squamous Cell Carcinoma	Drug: Nimotuzumab|Drug: Paclitaxel|Drug: Cisplatin|Radiation: Radiation|Procedure: Surgery	Peking University	Both	Adult	Phase 2|Phase 3	195	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ESCC002	11-Oct-14	Nov-14	Dec-17	21-Oct-14	Oct-14	No Study Results Posted	null	Dec-16	Disease-free survival|Overall survival|Pathological complete response of neoadjuvant treatment|The R0 resection rate|Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.	http://ClinicalTrials.gov/show/NCT02272699
6	NCT01688700	Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma	Recruiting	No Results Available	Esophageal Squamous Cell Carcinoma Resectable	Drug: Nimotuzumab combined with paclitaxel and cisplatin	Zhejiang Cancer Hospital	Both	Adult|Senior	Phase 2	60	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	NimoESCC	16-Sep-12	Sep-12	Sep-17	19-Sep-12	Sep-12	No Study Results Posted	null	Sep-13	Pathology complete remission rate|R0 resection rate|objective response rate|overall survival|tolerability and safety|Quality of life	http://ClinicalTrials.gov/show/NCT01688700
7	NCT01591135	A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma	Recruiting	No Results Available	Esophageal Squamous Cell Carcinoma	Drug: Paclitaxel plus 5-fluorouracil|Drug: Cisplatin plus 5-fluorouracil|Radiation: Radiation therapy|Radiation: Radiation therapy	Fudan University	Both	Adult|Senior	Phase 3	436	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ESO2012-01	18-Apr-12	Apr-12	Apr-17	2-May-12	May-12	No Study Results Posted	null	Apr-14	1-yr overall survivals|2-yr overall survival|3-yr overall survival|Disease progression-free survival|Local progression-free survival|Number and grade of Participants with Adverse Events	http://ClinicalTrials.gov/show/NCT01591135
8	NCT01258192	Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients	Completed	No Results Available	Esophageal Squamous Cell Carcinoma	Drug: albumin-bound  paclitaxel plus cisplatin	"Zhejiang Cancer Hospital|Second Affiliated Hospital, School of Medicine, Zhejiang University"	Both	Adult|Senior	Phase 2	35	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	ZhejiangCH-ESCC-01	3-Dec-10	Jan-11	Oct-12	28-Jul-14	Jul-14	No Study Results Posted	nabPCESCC	Oct-12	response to induction therapy|rate of complete pathological response|R0 resection rate.|3 years disease free and overall survival|safety and tolerability	http://ClinicalTrials.gov/show/NCT01258192
9	NCT01402180	Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy	Recruiting	No Results Available	Esophageal Squamous Cell Carcinoma	Biological: Nimotuzumab|Radiation: Radiation therapy|Radiation: radiation therapy|Drug: chemotherapy|Drug: chemotherapy	"Fudan University|Shanghai Chest Hospital|Shanghai Pulmonary Hospital, Shanghai, China|RenJi Hospital|Shanghai First People's Hospital"	Both	Adult|Senior	Phase 2|Phase 3	128	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	2010ESO_FU	25-Jul-11	Dec-10	Dec-15	25-Jul-11	Nov-10	No Study Results Posted	Nimotuzumab	Dec-13	Local control|Overall survival|Adverse Events	http://ClinicalTrials.gov/show/NCT01402180
10	NCT01391572	A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer	Recruiting	No Results Available	Esophageal Squamous Cell Carcinoma	Radiation: enlarge irradiation volume|Radiation: Small volume radiation|Drug: cisplatin|Drug: fluorouracil	"Fudan University|The First Affiliated Hospital of Soochow University|NANTONG TUMOR HOSPITAL|Jiangsu Cancer Institute & Hospital|Affiliated Hospital of Jiangsu University|Zhejiang Cancer Hospital|Wenzhou Medical University|Zhejiang University|The First Affiliated Hospital of Anhui Medical University|Anhui Provincial Hospital|Fujian Cancer Hospital|Shanghai Chest Hospital|Shanghai Pulmonary Hospital, Shanghai, China|RenJi Hospital"	Both	Adult|Senior	Phase 2	300	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	2011ESO_FU_01	8-Jul-11	Apr-11	null	20-Jul-11	Mar-11	No Study Results Posted	null	Dec-13	Survival|Safety and Tolerability|Failure pattern	http://ClinicalTrials.gov/show/NCT01391572
11	NCT01993784	Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.	Recruiting	No Results Available	Esophageal Squamous Cell Cancer	Drug: nimotuzumab	Peking University	Both	Adult|Senior	Phase 1|Phase 2	9	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	ESCC-N-301	16-Aug-13	Aug-13	Jun-14	20-Nov-13	Nov-13	No Study Results Posted	null	Mar-14	Objective response rate|adverse events	http://ClinicalTrials.gov/show/NCT01993784
12	NCT01496521	Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols	Not yet recruiting	No Results Available	"Carcinoma, Squamous Cell"	Drug: Aspirin|Dietary Supplement: Tea Polyphenols	Beijing Friendship Hospital	Both	Adult	Phase 3	600	Other	Interventional	"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)"	CREAT	15-Dec-11	Jan-12	Jan-13	17-Dec-11	Dec-11	No Study Results Posted	CREAT	Jun-12	occurrence of high grade dysplasia and invasive ESCC|the mortality of the participants|Number of participants with adverse events.	http://ClinicalTrials.gov/show/NCT01496521
13	NCT01398449	"Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0"	Recruiting	No Results Available	Esophageal Squamous Cell Carcinoma	Radiation: Elective nodal irradiation (ENI)|Other: Adjuvant chemotherapy only	"Fudan University|The First Affiliated Hospital of Soochow University|NANTONG TUMOR HOSPITAL|Jiangsu Cancer Institute & Hospital|Affiliated Hospital of Jiangsu University|Zhejiang Cancer Hospital|Wenzhou Medical University|Zhejiang University|The First Affiliated Hospital of Anhui Medical University|Anhui Provincial Hospital|Fujian Cancer Hospital|Shanghai Chest Hospital|Shanghai Pulmonary Hospital, Shanghai, China|RenJi Hospital"	Both	Adult|Senior	Phase 3	874	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	2011ESO_FU_02	13-Jul-11	Apr-11	Dec-17	19-Jul-11	Mar-11	No Study Results Posted	null	Dec-15	Overall survival|Locoregional control rate|Safety and Tolerability (incidence rate of adverse events)|Failure pattern	http://ClinicalTrials.gov/show/NCT01398449
14	NCT00815308	Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma	Completed	Has Results	Esophageal Cancer	Drug: cetuximab (Erbitux)|Drug: Paclitaxel|Drug: Cisplatin|Radiation: Radiation	Shandong Cancer Hospital and Institute|Chinese Academy of Medical Sciences|Beijing Cancer Hospital|Hebei Fourth Hospital|Jiangsu Cancer Institute & Hospital|RenJi Hospital|The Affiliated Cancer Hospital of Zhengzhou University|West China Hospital	Both	Adult|Senior	Phase 2	55	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	SDRTC-0901	29-Dec-08	Jan-09	Jul-10	4-Feb-11	Jul-09	15-Oct-10	EXCEL	Jul-10	Number of Participants With Overall Response Rate (RR)|Number of Participants With Toxicity|Participants With Overall Survival (OS) at 1 Year|Participants With Overall Survival (OS) at 3 Year|Participants With Progression Free Survival (PFS)|Number of Participants With K-ras Gene Mutation	http://ClinicalTrials.gov/show/NCT00815308
15	NCT01831531	Study of S-1 in Combination With Radiotherapy in Esophageal Cancer	Recruiting	No Results Available	Esophageal Squamous Cell Carcinoma	Drug: S-1|Radiation: Radiation therapy	Fudan University	Both	Adult|Senior	Phase 2	105	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	ESO2013-01	11-Apr-13	Mar-13	Mar-18	13-Apr-13	Apr-13	No Study Results Posted	null	Mar-15	Number of participants with adverse events|1-yr local control rate|2-yr local control rate|3-yr local control rate|1-yr overall survival|2-yr overall survival|3-yr overall survival	http://ClinicalTrials.gov/show/NCT01831531
16	NCT01670409	Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer	Recruiting	No Results Available	Esophageal Neoplasms	Radiation: SMART|Drug: PF	Chuangzhen Chen|Shantou University Medical College	Both	Adult|Senior	Phase 2	85	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	SUMC-ECA-001|ChiCTR-ONC-12002356	12-Aug-12	Aug-12	Sep-16	19-Nov-14	Nov-14	No Study Results Posted	null	Sep-16	Toxicities|local control rate|overall survival rate	http://ClinicalTrials.gov/show/NCT01670409
17	NCT02033538	Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus	Withdrawn	No Results Available	Squamous Cell Carcinoma of Esophagus	Drug: nanoparticle albumin-bound paclitaxel	Zhejiang University	Both	Adult|Senior	Phase 2	0	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	ZYTOP1403	16-Dec-13	Jan-14	Dec-16	4-Mar-15	Mar-15	No Study Results Posted	null	Dec-15	response rate|Overall survival|Progression-free survival|Adverse events	http://ClinicalTrials.gov/show/NCT02033538
18	NCT02041819	Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus	Withdrawn	No Results Available	Squamous Cell Carcinoma of Esophagus	Drug: Nimotuzumab	Zhejiang University	Both	Adult|Senior	Phase 2	0	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	ZYTOP1405	10-Jan-14	Feb-14	Jan-17	4-Mar-15	Mar-15	No Study Results Posted	null	Jan-16	response rate|Overall survival|Progression-free survival|Adverse events	http://ClinicalTrials.gov/show/NCT02041819
19	NCT01930630	ESI With EUS to Differentiate T3 and T4 ESCC	Not yet recruiting	No Results Available	Esophageal Cancer	Device: Extraesophageal saline injection (ESI)	Sun Yat-sen University	Both	Adult	Phase 1	10	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label	ESI-2013|2012-FXY-006	20-Aug-13	Oct-13	Oct-14	22-Aug-13	Aug-13	No Study Results Posted	ESI	Sep-14	Number of participants with adverse events|Efficacy of extraesophageal saline separating esophagus from adjacent organs detected by EUS or computerized tomography (CT) just after ESI	http://ClinicalTrials.gov/show/NCT01930630
20	NCT02319187	Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial	Recruiting	No Results Available	Esophageal Neoplasms	Drug: S1|Drug: S-1|Drug: irinotecan	Chinese Academy of Medical Sciences	Both	Adult|Senior	Phase 3	240	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	CH-GI-064	9-Dec-14	Dec-14	Jun-17	1-Jan-15	Dec-14	No Study Results Posted	null	Dec-16	progression free survival|Adverse  Events|overall survival|response rate|quality of life	http://ClinicalTrials.gov/show/NCT02319187
21	NCT02025036	Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer	Recruiting	No Results Available	Stage III Esophageal Squamous Cell Carcinoma|Stage II Esophageal Squamous Cell Carcinoma	Drug: Capecitabine(Aibin)|Drug: Oxaliplatin(Aiheng)|Radiation: Radiotherapy	The First Affiliated Hospital of Henan University of Science and Technology	Both	Adult|Senior	Phase 3	495	Other	Interventional	"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)"	FirstHenanUST	17-Nov-13	Oct-14	Dec-22	5-Dec-14	Jul-14	No Study Results Posted	CRTCOESC	Dec-17	"overall survival, OS|progression-free survival|overall remission rate, ORR|serious adverse event|quality of life, Qol|pathologic complete response rate|R0 resection rate"	http://ClinicalTrials.gov/show/NCT02025036
22	NCT01688908	Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)	Recruiting	No Results Available	Esophageal Squamous Cell Carcinomas	Procedure: Endoscopy Screening	Peking University	Both	Adult|Senior		32000	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Screening|Masking: Single Blind (Outcomes Assessor)	201202014	17-Sep-12	Jan-12	Dec-22	17-Sep-12	Sep-12	No Study Results Posted	ESECC	Dec-17	Esophageal cancer specific mortality|Cumulative incidence of advanced esophageal cancer	http://ClinicalTrials.gov/show/NCT01688908
23	NCT02011594	Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma	Withdrawn	No Results Available	Stage IV Esophageal Squamous Cell Carcinoma	Drug: Nimotuzumab|Drug: Placebo	Zhejiang University	Both	Adult|Senior	Phase 2	0	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ZYTOP1407	7-Dec-13	Jan-14	Feb-15	11-Feb-15	Feb-15	No Study Results Posted	null	Jan-15	PFS (Progression free survival)|Objective Response Rate|Overall survival (OS)|Disease control rate (DCR)	http://ClinicalTrials.gov/show/NCT02011594
24	NCT01137123	Improve the Treatment of Thoracic Esophageal Cancer	Recruiting	No Results Available	Thoracic Esophageal Squamous Cell Carcinoma	Drug: adjuvant chemotherapy|Procedure: standard two field Lymphadenectomy|Procedure: Total two field Lymphadenectomy|Procedure: three field Lymphadenectomy	Sun Yat-sen University	Both	Child|Adult|Senior	Phase 3	2615	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	2007044	3-Jun-10	Apr-10	Sep-16	19-Oct-12	Apr-10	No Study Results Posted	null	Jan-13	survival rate	http://ClinicalTrials.gov/show/NCT01137123
25	NCT02094105	Endoscopic Screening on Esophageal Cancer	Completed	No Results Available	Esophageal Squamous Cell Carcinoma	Procedure: Endoscopy examination with iodine staining	Chinese Academy of Medical Sciences	Both	Adult|Senior		45386	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label	ESCC01	20-Mar-14	Nov-99	Dec-13	20-Mar-14	Mar-14	No Study Results Posted	null	Dec-09	"incidence and mortality of ESCC|Cumulative incidence and mortality of total cancer, and gastric cardia cancer"	http://ClinicalTrials.gov/show/NCT02094105
26	NCT01745107	Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;	Recruiting	No Results Available	Esophageal Neoplasm|Esophageal Cancer TNM Staging Primary Tumor (T) T2|Esophageal Cancer TNM Staging Primary Tumor (T) T3|Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0|Esophageal Cancer TNM Staging Distal Metastasis (M) M0	Radiation: Prophylactic postoperative radiation therapy	Chinese Academy of Medical Sciences|Sichuan Cancer Hospital and Research Institute|Tianjin Medical University Cancer Institute and Hospital	Both	Adult|Senior	Phase 3	240	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	Z121107001012004	6-Dec-12	Nov-12	Nov-20	28-Dec-12	Dec-12	No Study Results Posted	IMRT	Nov-15	Disease-free survival time|overall survival time	http://ClinicalTrials.gov/show/NCT01745107
27	NCT02047305	Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia	"Active, not recruiting"	No Results Available	ESOPHAGEAL SQUAMOUS CELL CARCINOMA	Device: Radiofrequency Ablation	"Covidien, GI Solutions"	Both	Adult|Senior		100	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	B300	24-Jan-14	Jan-09	Sep-16	12-Mar-15	Jan-14	No Study Results Posted	null	Aug-11	Complete response|Safety	http://ClinicalTrials.gov/show/NCT02047305
28	NCT01973725	Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy	Recruiting	No Results Available	Esophageal Squamous Cell Carcinoma	Drug: Icotinib Hydrochloride	Yuhong Li|Sun Yat-sen University	Both	Adult|Senior	Phase 2	50	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	ICO-29	25-Oct-13	Oct-13	Dec-15	17-Sep-14	Sep-14	No Study Results Posted	null	Dec-15	Disease control rate|Overall survival|Time to progression|Safety|Quality of life	http://ClinicalTrials.gov/show/NCT01973725
29	NCT02350517	Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer	Recruiting	No Results Available	Esophageal Squamous Cell Carcinoma	Drug: Paclitaxel+Nedaplatin+Endostar	Yuhong Li|Sun Yat-sen University	Both	Adult|Senior	Phase 2	52	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	Endo-17	24-Jan-15	Jan-15	Dec-18	24-Jan-15	Jan-15	No Study Results Posted	null	Dec-17	Progression free survival|Overall survival|Overall response rate (ORR)|Number of participants with AEs and SAEs as a measure of Safety|Quality of life	http://ClinicalTrials.gov/show/NCT02350517
30	NCT02034968	Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma	Withdrawn	No Results Available	Stage IV Esophageal Squamous Cell Carcinoma	Drug: Nimotuzumab	Zhejiang University	Both	Adult|Senior	Phase 2	0	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	ZYTOP1406	10-Jan-14	Feb-14	Jan-17	4-Mar-15	Mar-15	No Study Results Posted	null	Jan-16	Progression free survival(PFS)|Objective Response Rate	http://ClinicalTrials.gov/show/NCT02034968
31	NCT02016274	Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer	Recruiting	No Results Available	Esophageal Squamous Cell Cancer	"Other: Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy"	Shen Lin|Peking University	Both	Adult|Senior	Phase 2	70	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CGOG7001	7-Dec-13	Dec-13	Jul-16	13-Dec-13	Dec-13	No Study Results Posted	null	Dec-15	progression free survival|overall survival	http://ClinicalTrials.gov/show/NCT02016274
32	NCT02016287	Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer	Recruiting	No Results Available	Esophageal Squamous Cell Cancer|Elderly Patients	"Other: Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy"	Shen Lin|Peking University	Both	Senior	Phase 2	50	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CGOG7002	7-Dec-13	Dec-13	Jul-16	13-Dec-13	Dec-13	No Study Results Posted	null	Dec-15	progression free survival|overall survival	http://ClinicalTrials.gov/show/NCT02016287
33	NCT02133612	Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma	Completed	No Results Available	Esophageal Cancer	Drug: paclitaxel; cisplatin	Chinese Academy of Medical Sciences	Both	Adult|Senior	Phase 2	43	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CH-GI-026	5-May-14	Dec-07	May-14	6-May-14	May-14	No Study Results Posted	null	May-12	3 year overall survival|3 year disease-free survival	http://ClinicalTrials.gov/show/NCT02133612
34	NCT01854749	S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study	Recruiting	No Results Available	Esophageal Squamous Cell Carcinoma	Drug: S1 combined with cisplatin	Fudan University	Both	Adult|Senior	Phase 2	48	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	S1- ESCC -CJH	10-May-13	Nov-11	null	13-May-13	May-13	No Study Results Posted	null	Dec-13	Progression Free Survival	http://ClinicalTrials.gov/show/NCT01854749
35	NCT01630174	IMRT/Pemetrexed/Cisplatin in Esophageal Cancer	Recruiting	No Results Available	Esophageal Cancer		Shandong Cancer Hospital and Institute	Both	Adult|Senior		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	phase 1 pem IMRT	27-Jun-12	Oct-09	null	27-Jun-12	Jun-12	No Study Results Posted	null	null		http://ClinicalTrials.gov/show/NCT01630174
36	NCT01216527	Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer	Recruiting	No Results Available	Squamous Cell Esophageal Carcinoma	Procedure: Neo-adjuvant Chemoradiotherapy followed by Surgery|Procedure: surgery	Sun Yat-sen University|Cancer Hospital of Shantou University|Shanghai Chest Hospital|Fudan University|Zhejiang Cancer Hospital|Taizhou Hospital|The Second People's Hospital of Sichuan|Tianjin Medical University Cancer Institute and Hospital	Both	Adult|Senior	Phase 3	430	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	2007048	6-Oct-10	Jun-07	Dec-19	23-Nov-14	Nov-14	No Study Results Posted	null	Dec-19	Overall survival rate|toxicities of neo-adjuvant chemoradiotherapy|assessment in perioperation|efficacy of neo-adjuvant chemoradiotherapy|Disease free survival rate	http://ClinicalTrials.gov/show/NCT01216527
37	NCT01486992	mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus	Recruiting	No Results Available	Advanced Esophageal Carcinoma	Drug: mFOLFIRI+Nimotuzumab	Peking University	Both	Adult|Senior	Phase 2	40	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	N+FOLFIRI-AEC-4	22-Nov-11	Nov-11	Nov-12	11-Jan-12	Nov-11	No Study Results Posted	null	Nov-12	overall survival|adverse events|progression-free survival|response rate|disease control rate	http://ClinicalTrials.gov/show/NCT01486992
38	NCT02188615	Study of Neo-adjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Squamous Cell Esophageal Cancer	Recruiting	No Results Available	Squamous Cell Esophageal Carcinoma	Procedure: Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Drug: Cisplatin|Device: Mckeown MIE	Chengchu Zhu|Sun Yat-sen University|Fudan University|Taizhou Hospital	Both	Adult|Senior	Phase 2	120	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	BZhang|2011C13039-2	28-Jun-14	Jun-11	Jul-19	9-Jul-14	Jul-14	No Study Results Posted	NACRFMIE	Jun-15	Overall survival rate|Disease free survival|the opportunity of MIE after neo-adjuvant chemoradiotherapy|Side effects of neo-adjuvant chemoradiotherapy|Duration of surgery|Quantity of bleeding|number of lymph nodes retrieved|Days of  postoperative stay|Rate of Operative Complication|Mortality of perioperation	http://ClinicalTrials.gov/show/NCT02188615
39	NCT00341523	Early Detection of Esophageal Cancer	"Active, not recruiting"	No Results Available	"Esophageal Neoplasms|Stomach Neoplasms|Endoscopy, Gastrointestinal|Digestive System Endoscopic Surgical Procedures|Cytology"		National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	Both	Adult|Senior		8000	NIH	Observational	Time Perspective: Prospective	999995026|OH95-C-N026	19-Jun-06	May-94	null	11-Dec-14	Dec-14	No Study Results Posted	null	null	Esophageal squamous dysplasia|Esophageal squamous cell carcinoma (ESCC)|Death from any cause	http://ClinicalTrials.gov/show/NCT00341523
40	NCT01704690	Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer	Recruiting	No Results Available	Esophageal Cancer	Drug: S-1 and Paclitaxel|Drug: Paclitaxel and Cisplatin|Drug: 5-FU and Cisplatin	Peking University	Both	Adult|Senior	Phase 2|Phase 3	80	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ESCC001	4-Oct-12	Aug-12	Dec-15	13-Oct-14	Oct-14	No Study Results Posted	null	Dec-15	Response rate|The median overall survival time|Median progression-free time|Number of Participants with Adverse Events and the degree of each adverse event	http://ClinicalTrials.gov/show/NCT01704690
41	NCT01051765	Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial	Recruiting	No Results Available	Advanced Esophageal Squamous Carcinoma	Drug: irinotecan/cisplatin	Peking University	Both	Adult|Senior	Phase 2	60	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	IP-AEC1	19-Jan-10	Aug-09	Aug-12	19-Jan-10	May-09	No Study Results Posted	null	Aug-11	overall survival|PFS|response rate|adverse events|polymorphism of UGT1A	http://ClinicalTrials.gov/show/NCT01051765
42	NCT01336049	Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer	Recruiting	No Results Available	Esophageal Squamous Cell Cancer	Drug: Nimotuzumab	Peking University	Both	Adult|Senior	Phase 2	70	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	N+TP-AEC3	29-Mar-11	Mar-11	null	14-Apr-11	Mar-11	No Study Results Posted	null	Dec-11	Objective response rate|overall survival of all participants|progression free survival|adverse events	http://ClinicalTrials.gov/show/NCT01336049
43	NCT01752205	Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma	Recruiting	No Results Available	Esophageal Squamous Carcinoma	Drug: Paclitaxel|Drug: Erlotinib|Radiation: Radiation therapy	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences	Both	Adult|Senior	Phase 3	120	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ESCC-307PLAH-XJM	16-Dec-12	Nov-12	Nov-14	16-Dec-12	Dec-12	No Study Results Posted	ESCC-307PLAH	May-14	Progression free survival|Tumor response rate|disease control rate|overall survival|adverse events	http://ClinicalTrials.gov/show/NCT01752205
44	NCT00642239	A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma	Recruiting	No Results Available	Esophageal Carcinoma	Drug: placebo|Drug: Sodium Glycididazole	"Shandong Luye Pharmaceutical Co., Ltd."	Both	Adult|Senior	Phase 4	48	Industry	Interventional	"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)"	CMNa-ESO-01-2007	21-Mar-08	Apr-08	Dec-09	13-May-08	May-08	No Study Results Posted	null	Dec-08	tumour local control rate|survival rate	http://ClinicalTrials.gov/show/NCT00642239
45	NCT02375997	Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer	Recruiting	No Results Available	Metastatic Esophageal Squamous Carcinoma|Gastric Cancer	Other: Palliative care	Peking University	Both	Adult|Senior	Phase 3	592	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	EPC-UPGI	27-Oct-14	Oct-14	Oct-18	24-Feb-15	Feb-15	No Study Results Posted	null	Oct-17	Overall survival|Quality of life|Overall response rate|Adverse event	http://ClinicalTrials.gov/show/NCT02375997
46	NCT01225523	Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus	Completed	No Results Available	Squamous Carcinoma of Esophagus|Esophagus Disorders	Drug: Paclitaxel; Cisplatin; 5-Fluorouracil|Drug: Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine	Xi’an Jiaotong University College of Medicine	Both	Adult|Senior	Phase 1	350	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	ZY-01	19-Oct-10	Jan-97	Jan-10	20-Oct-10	Sep-10	No Study Results Posted	null	Dec-08	Overall survival rate|Progression-free survival|Pathological remission rate|Resectability rate|Operative and postoperative complication rate|30-day mortality|Toxicity of preoperative and postoperative chemotherapy|Rate of local recurrences and metastasis	http://ClinicalTrials.gov/show/NCT01225523
47	NCT01626209	A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors	Completed	No Results Available	"Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology"	Drug: BKM120	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 1	32	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CBKM120Z2102	20-Jun-12	Jul-12	Apr-14	5-Feb-15	Feb-15	No Study Results Posted	null	Apr-14	"Dose Limiting Toxicity (DLT)|Type, frequency and severity of of Adverse Events (AEs) (based on CTCAE version 4.03|Laboratory and vital sign parameters|Pharmacokinetics: plasma concentration-time profiles of BKM120 for Cmax|Pharmacokinetics: plasma concentration-time profiles of BKM120 for Tmax|Pharmacokinetics: plasma concentration-time profiles of BKM120 for AUCtlast|Pharmacokinetics: plasma concentration-time profiles of BKM120 for AUCtau|Pharmacokinetics: plasma concentration-time profiles of BKM120 for AUCinf|Pharmacokinetics: plasma concentration-time profiles of BKM120 for AUC%Extrap|Pharmacokinetics: plasma concentration-time profiles of BKM120 for CL/F|Pharmacokinetics: plasma concentration-time profiles of BKM120 for Racc|Pharmacokinetics: plasma concentration-time profiles of BKM120 for T1/2acc|Pharmacokinetics: plasma concentration-time profiles of BKM120 for Vss/F|Pharmacokinetics: plasma concentration-time profiles of BKM120 for Rsqadj|Pharmacokinetics: plasma concentration-time profiles of BKM120 for other PK parameters|Objective Response Rate (ORR)|Time to Progression (TTP)"	http://ClinicalTrials.gov/show/NCT01626209
